"These results indicate that PBT2 is having an impact on the underlying biology of Alzheimer's, which is very exciting," Cummings said. "This is a critical proof of concept, and the safety and efficacy demonstrated by PBT2 in this study warrant evaluation in larger scale clinical trials in Alzheimer's."
A Phase IIb trial of a Tau Aggregation Inhibitor Therapy
As an alternative to anti-amyloid therapies for Alzheimer's, researchers continue to examine a variety of treatments and targets with the potential to curb the disease. This includes presenting data supporting the viability of therapies targeting tau protein and its aggregation into the "tangles" originally discovered by Alois Alzheimer.
Previous research has shown that the buildup of brain lesions known as neurofibrillary tangles, which are composed of a short fragment of a protein called tau, is correlated with increasing levels of dementia symptoms. And, these tangles first appear in the brain long before symptoms of the disease become clinically apparent. Methylthioninium chloride (MTC, or brand name rember(TM)) has been shown in the test tube to dissolve tau tangle filaments and prevent aggregation of tau into tangles. MTC has also been shown to block the toxic effects of aggregated tau in cells. In animal models, MTC has demonstrated cognitive and behavioral benefits in line with reduced tau pathology.
In research reported at ICAD 2008, Claude M. Wischik, Professor in
Mental Health, University of Aberdeen, United Kingdom and Chairman, TauRx
Therapeutics, Singapore, and colleagues conducted a 24-week, double-blind,
randomized, dose-ranging, parallel design trial of MTC monotherapy in 321
people with Alzheimer's at 17 centers in the United Kingdom and Singapore,
followed by a 60-week, blinded, active treatment extension. The control
group received placebo for the initial 24 weeks and then a minimal efficacy
dose subsequently. The primar
|SOURCE Alzheimer's Association|
Copyright©2008 PR Newswire.
All rights reserved